Curis SEC Filings

Curis, Inc. reports an amended Schedule 13G/A showing Thomas A. Satterfield, Jr. beneficially owns 3,957,950 shares of Common Stock, representing 9.9% (rounded) of outstanding stock.

The filing states 38,978,693 shares outstanding as of May 8, 2026 and describes warrants and pre-funded warrants that are subject to a 9.99% exercise limit. The report breaks out ownership held directly and through affiliated entities.

Curis, Inc. reported a net loss of $24.2 million for the three months ended March 31, 2026, more than double the prior-year period, as it transitions to being fully dependent on its IRAK4/FLT3 inhibitor emavusertib. Revenue fell to $0 from $2.4 million after the 2025 sale of Erivedge royalty rights. Research and development expenses declined 24% to $6.4 million, while general and administrative costs rose 27% to $5.1 million, driven largely by the January 2026 PIPE financing.

Curis ended the quarter with $15.0 million in cash and cash equivalents and used $9.0 million of cash in operations. The company explicitly states there is “substantial doubt” about its ability to continue as a going concern within one year without substantial additional capital, citing an accumulated deficit of about $1.3 billion and ongoing operating losses. Management plans to seek more financing and strategic options while focusing development on emavusertib in PCNSL and CLL.

Curis, Inc. reported first quarter 2026 results showing a larger net loss as it advances emavusertib across multiple cancer trials. Net loss was $24.2 million, or $1.25 per share, compared with $10.6 million, or $1.25 per share, a year earlier.

The company reported no revenue after selling its Erivedge royalty stream in late 2025, versus $2.4 million in Q1 2025. Research and development expenses fell to $6.4 million, while general and administrative costs rose to $5.1 million, largely from a January 2026 PIPE financing. A new $12.7 million other expense line reflects warrant liability revaluation. Curis ended March 31, 2026 with $15.0 million in cash and cash equivalents and about 40.0 million shares outstanding, and believes existing cash plus potential Series B warrant proceeds could fund operations into the second half of 2027, though it states current cash is insufficient for the next 12 months.

Curis, Inc. reports that Nasdaq has issued a Delist Determination Letter because the bid price of its common stock closed below the $1.00 per share minimum for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). As a result, Curis’ securities are scheduled for suspension and delisting from the Nasdaq Capital Market at the opening of trading on May 6, 2026, unless the company requests a hearing by May 4, 2026. Curis intends to make a timely hearing request, which would stay further delisting actions, but it cautions there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.

Curis, Inc. reported that Nantahala Capital Management, LLC and its managers Wilmot B. Harkey and Daniel Mack may be deemed beneficial owners of 4,215,165 shares of Curis common stock as of March 31, 2026. The reported stake represents 9.99% of the outstanding class based on 39,978,693 shares outstanding reported in the issuer's Form 10-K filed March 24, 2026. The 4,215,165 shares include 2,215,165 shares that may be acquired within sixty days through the exercise of warrants. Nantahala and each manager report shared voting and dispositive power for the 4,215,165 shares; no sole voting or dispositive power is reported.

Curis, Inc. is holding a virtual annual stockholder meeting on May 19, 2026 at 11:00 a.m. Eastern Time to vote on key corporate matters. Stockholders will elect two Class III directors, cast an advisory vote on executive pay, and ratify PricewaterhouseCoopers LLP as independent auditor for 2026.

The company is also asking stockholders to approve an amendment to its Restated Certificate of Incorporation to increase the number of authorized shares of common stock and to allow a possible adjournment if additional proxies are needed for that proposal. Stockholders of record at the close of business on March 23, 2026, when 39,978,693 common shares were outstanding, may vote online, by phone, by mail, or during the virtual meeting.

The proxy statement details board structure, committee responsibilities, and governance practices, including fully independent audit, compensation, and nominating committees. It also outlines environmental, social, and human capital initiatives, and discloses beneficial ownership, with several institutional investors each reporting approximately 9.99% beneficial stakes, subject to warrant-based beneficial ownership limitations.

Curis, Inc. will hold its 2026 annual meeting of stockholders virtually on May 19, 2026 to elect two Class III directors and approve several proposals, including an Authorized Shares Proposal to increase the number of authorized shares of common stock. The record date for voting is March 23, 2026, and 39,978,693 shares were outstanding on that date.

The board recommends votes FOR all proposals, including the proposed amendment to the Restated Certificate of Incorporation to increase authorized shares and a non-binding advisory vote on executive compensation. The proxy materials will be mailed or emailed in April 2026 and shareholders may vote online, by phone, by mail, or during the virtual meeting.

Curis, Inc. ownership disclosure: Nantahala Capital Management, LLC and its managers report beneficial ownership of 4,215,165 shares of Curis Common Stock as of March 31, 2026. Each of the reporting persons — Nantahala, Wilmot B. Harkey and Daniel Mack — is shown as beneficial owner of 9.99% of the class based on a cited 2,215,165 shares outstanding figure from a Form 10-K filed March 27, 2026. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that Nantahala and the two managers have shared voting and dispositive power over the 4,215,165 shares.